These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30376242)

  • 1. Osteoporosis Management Following Teriparatide Therapy For Vertebral Fractures: Are Patients On Correct Maintenance Therapy?
    O'Connor MB; Bond U; Yousif T
    Ir Med J; 2018 Mar; 111(3):724. PubMed ID: 30376242
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases.
    Rubery PT; Bukata SV
    J Spinal Disord Tech; 2010 Apr; 23(2):151-5. PubMed ID: 20051918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study.
    Ijuin A; Yoshikata H; Asano R; Tsuburai T; Kikuchi R; Sakakibara H
    Taiwan J Obstet Gynecol; 2017 Dec; 56(6):863-866. PubMed ID: 29241936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis].
    Uelbelhart B; Rizzoli R
    Rev Med Suisse; 2012 Jan; 8(324):109-10, 112-5. PubMed ID: 23185820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the efficacy of teriparatide treatment for osteoporosis on lumbar fusion surgery outcomes: a systematic review and meta-analysis.
    Fatima N; Massaad E; Hadzipasic M; Shankar GM; Shin JH
    Neurosurg Rev; 2021 Jun; 44(3):1357-1370. PubMed ID: 32728969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?
    Anagnostis P; Karras SN; Goulis DG
    Curr Med Res Opin; 2014 Jun; 30(6):1177-8. PubMed ID: 24579907
    [No Abstract]   [Full Text] [Related]  

  • 14. [Daily subcutaneous injection of teriparatide : the progress and current issues].
    Yano S; Sugimoto T
    Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Author's response to letter to the editor.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 Aug; 30(8):1627-8. PubMed ID: 24730639
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2014 Mar; 24(3):401-6. PubMed ID: 24576937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.].
    Miyauchi A
    Clin Calcium; 2016; 26(11):1583-1595. PubMed ID: 27777391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Importance of teriparatide in the treatment of osteoporosis].
    Yamauchi M
    Clin Calcium; 2016 Jun; 26(6):905-13. PubMed ID: 27230847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.